anti-EGFR/anti-c-Met monoclonal antibody FPI-2053

A humanized bispecific monoclonal antibody targeting epidermal growth factor receptor (EGFR) and hepatocyte growth factor receptor (HGFR; c-Met), that can potentially be used as a ligand in radiotherapy. Upon administration, anti-EGFR/anti-c-Met monoclonal antibody FPI-2053 simultaneously targets and binds to the extracellular domains of both EGFR and c-Met expressed on cancer cells. EGFR and c-Met, both upregulated or mutated in a variety of tumor cell types, play key roles in tumor cell proliferation.